Stock Research for CPRX

CPRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CPRX Stock Chart & Research Data

The CPRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CPRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CPRX Due diligence Resources & Stock Charts

The CPRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CPRX Detailed Price Forecast - CNN Money CNN View CPRX Detailed Summary - Google Finance
Yahoo View CPRX Detailed Summary - Yahoo! Finance Zacks View CPRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CPRX Trends & Analysis - Trade-Ideas Barrons View CPRX Major Holders - Barrons
NASDAQ View CPRX Call Transcripts - NASDAQ Seeking View CPRX Breaking News & Analysis - Seeking Alpha
Spotlight View CPRX Annual Report - CompanySpotlight.com OTC Report View CPRX OTC Short Report - OTCShortReport.com
TradeKing View CPRX Fundamentals - TradeKing Charts View CPRX SEC Filings - Bar Chart
WSJ View Historical Prices for CPRX - The WSJ Morningstar View Performance/Total Return for CPRX - Morningstar
MarketWatch View the Analyst Estimates for CPRX - MarketWatch CNBC View the Earnings History for CPRX - CNBC
StockMarketWatch View the CPRX Earnings - StockMarketWatch MacroAxis View CPRX Buy or Sell Recommendations - MacroAxis
Bullish View the CPRX Bullish Patterns - American Bulls Short Pains View CPRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CPRX Stock Mentions - StockTwits PennyStocks View CPRX Stock Mentions - PennyStockTweets
Twitter View CPRX Stock Mentions - Twitter Invest Hub View CPRX Investment Forum News - Investor Hub
Yahoo View CPRX Stock Mentions - Yahoo! Message Board Seeking Alpha View CPRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CPRX - SECform4.com Insider Cow View Insider Transactions for CPRX - Insider Cow
CNBC View CPRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CPRX - OTC Markets
Yahoo View Insider Transactions for CPRX - Yahoo! Finance NASDAQ View Institutional Holdings for CPRX - NASDAQ


Stock Charts

FinViz View CPRX Stock Insight & Charts - FinViz.com StockCharts View CPRX Investment Charts - StockCharts.com
BarChart View CPRX Stock Overview & Charts - BarChart Trading View View CPRX User Generated Charts - Trading View




Latest Financial News for CPRX


Catalyst (CPRX) Up 16% Since Last Earnings Report: Can It Continue?
Posted on Thursday September 06, 2018

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.


Healthcare Wiz Mitchell Blutt Bets Big on These 3 Biotech Stocks
Posted on Thursday August 30, 2018

Hedge fund manager Mitchell J. Blutt of the $1.5 billion Consonance Capital fund has made some intriguing portfolio shifts in the last quarter, including boosting his position in biopharma firm Catalyst Pharmaceuticals (NASDAQ:CPRX) and initiating stakes in drug makers Verastem (NASDAQ:VSTM) and Sesen Bio (NYSE:SESN). Blutt is seizing the opportunity with Catalyst, dialing up his hedge fund firm’s stake in the company to the tune of a 22% boost up.


Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference
Posted on Wednesday August 29, 2018

Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at Rodman & Renshaw’s 20th Annual Global Investment Conference, which is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City. Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, and spinal muscular atrophy (SMA) type 3.


Why Catalyst Pharmaceuticals (CPRX) Is a $6 Stock
Posted on Wednesday August 22, 2018

Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have been waiting for two-and-a-half years since its marketing application was originally submitted to see the company's flagship candidate Firdapse approved, but they may not have to wait much longer -- the FDA is expected to make a decision by November 28. Catalyst had previously submitted an NDA for Firdapse off one positive pivotal trial in Lambert-Eaton myasthenic syndrome (LEMS). While the company believed this single trial, together with other information, would be adequate for approval, the FDA issued a Refuse-to-File letter in early 2016.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.